These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 1825568)
1. On the mechanism of the prolonged action in man of GR32191, a thromboxane receptor antagonist. Ritter JM; Doktor HS; Benjamin N; Barrow SE; Stewart-Long P Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():351-4. PubMed ID: 1825568 [TBL] [Abstract][Full Text] [Related]
2. Preliminary assessment of a novel thromboxane A2 receptor-blocking drug, GR32191, in healthy subjects. Thomas M; Lumley P Circulation; 1990 Jan; 81(1 Suppl):I53-8; discussion I59-60. PubMed ID: 2136818 [TBL] [Abstract][Full Text] [Related]
3. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion. Hornby EJ; Foster MR; McCabe PJ; Stratton LE Thromb Haemost; 1989 Jun; 61(3):429-36. PubMed ID: 2529661 [TBL] [Abstract][Full Text] [Related]
4. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Lumley P; White BP; Humphrey PP Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074 [TBL] [Abstract][Full Text] [Related]
5. Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191. Humphrey PP; Hallet P; Hornby EJ; Wallis CJ; Collington EW; Lumley P Circulation; 1990 Jan; 81(1 Suppl):I42-52; discussion I59-60. PubMed ID: 2136817 [TBL] [Abstract][Full Text] [Related]
6. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation. Vezza R; Nenci GG; Gresele P J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121 [TBL] [Abstract][Full Text] [Related]
7. Effects of a selective thromboxane receptor antagonist (GR32191B) and of glyceryl trinitrate on bleeding time in man. Ritter JM; Benjamin N; Doktor HS; Barrow SE; Mant TG; Schey S; Stewart-Long P Br J Clin Pharmacol; 1990 Apr; 29(4):431-6. PubMed ID: 2139338 [TBL] [Abstract][Full Text] [Related]
8. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Watts IS; Wharton KA; White BP; Lumley P Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620 [TBL] [Abstract][Full Text] [Related]
9. The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. Takahara K; Murray R; FitzGerald GA; Fitzgerald DJ J Biol Chem; 1990 Apr; 265(12):6836-44. PubMed ID: 2139029 [TBL] [Abstract][Full Text] [Related]
10. Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction. Beasley RC; Featherstone RL; Church MK; Rafferty P; Varley JG; Harris A; Robinson C; Holgate ST J Appl Physiol (1985); 1989 Apr; 66(4):1685-93. PubMed ID: 2525122 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers. Uematsu T; Nagashima S; Mizuno A; Hirano K; Nakashima M J Clin Pharmacol; 1991 Sep; 31(9):815-22. PubMed ID: 1839540 [TBL] [Abstract][Full Text] [Related]
12. The pharmacodynamics and pharmacokinetics of a novel thromboxane receptor blocking drug vapiprost (GR32191) after single intravenous doses in healthy subjects. Thomas M; Keery RJ; Charter MK; Scully NL; Chilton JE; Lumley P Br J Clin Pharmacol; 1991 Aug; 32(2):181-6. PubMed ID: 1834144 [TBL] [Abstract][Full Text] [Related]
13. Maximal blockade of TxA2 without compromised PGI2 formation; a superior profile of the TxA2 receptor blocking drug GR32191 over aspirin. Lumley P; Keery RJ; Wharton KA; White BP; Watts IS Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():603-6. PubMed ID: 1825385 [No Abstract] [Full Text] [Related]
15. Characteristics of the binding of [3H]-GR32191 to the thromboxane (TP-) receptor of human platelets. Armstrong RA; Humphrey PP; Lumley P Br J Pharmacol; 1993 Oct; 110(2):539-47. PubMed ID: 8242228 [TBL] [Abstract][Full Text] [Related]
16. Comparison of GR32191, R68070 and CV-4151 upon U-46619- and collagen-induced platelet aggregation in vitro and ex vivo. Watts IS; White BP; Wharton KA; Lumley P Br J Pharmacol; 1989 Dec; 98 Suppl():842P. PubMed ID: 2611538 [No Abstract] [Full Text] [Related]
17. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle. Shaw LA; Batey AJ; Coker SJ Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543 [TBL] [Abstract][Full Text] [Related]
18. Platelet reactivity in vitro in relation to thromboxane in healthy pregnancy. Horn EH; Hardy E; Cooper J; Heptinstall S; Rubin PC Thromb Haemost; 1996 Feb; 75(2):346-51. PubMed ID: 8815588 [TBL] [Abstract][Full Text] [Related]
19. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate. Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331 [TBL] [Abstract][Full Text] [Related]
20. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets. Mais DE; Burch RM; Saussy DL; Kochel PJ; Halushka PV J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]